Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	25.95B +6.5%
Revenue (ttm)	4.98B -25.5%
Net Income	2.18B -1.6%
EPS	2.83 -1.9%
Shares Out	770.09M
PE Ratio	13.74
Forward PE	n/a
Dividend	4.68 (12.04%)
Ex-Dividend Date	Jul 10, 2026

Volume	5,671,663
Open	38.66
Previous Close	38.86
Day's Range	38.04 - 39.39
52-Week Range	34.70 - 50.97
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 15, 2026

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 3,890
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2025, SHA:600329's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 21, 2026

Data Sources Report a data error